131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

NCT03275402 PHASE2, PHASE3 TERMINATED Results posted

Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety

Details

Lead sponsor	Y-mAbs Therapeutics
Phase	PHASE2, PHASE3
Status	TERMINATED
Enrolment	52
Start date	Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neuroblastoma
• CNS Metastases
• Leptomeningeal Metastases

Interventions

• 131I-omburtamab

Countries

Denmark, Japan, United States, Spain